Voranigo (vorasidenib) — Medica
Grade 2 oligodendroglioma with IDH1 or IDH2 mutation
Initial criteria
- Patient is age ≥ 12 years
- Patient has a susceptible isocitrate dehydrogenase-1 (IDH1) or IDH2 mutation-positive disease
- Patient meets ONE of the following (i or ii): i. Patient has ≥ Grade 2 oligodendroglioma; OR ii. Patient has ≥ Grade 2 astrocytoma
- Patient has had prior surgery, including biopsy, sub-total resection, or gross total resection
Approval duration
1 year